NSB Share Price Performance
Recent NSB News & Updates
No updates
NeuroScientific Biopharmaceuticals Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0.0036
- Gross Margin
- 98.98%
- Net Profit Margin
- 53.66%
- Debt/Equity Ratio
- 0%
NeuroScientific Biopharmaceuticals Limited Competitors
About NSB
- Founded
- 2002
- Employees
- n/a
- CEO
- WebsiteView website
NeuroScientific Biopharmaceuticals Limited engages in the research and development of novel peptide-based pharmaceutical products. The company is involved in the development of therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. Its lead drug candidates include EmtinB for treatment of neurodegenerative Alzheimer’s disease, multiple scierosis, glaucoma, optic nerve atrophy, and other diseases. The company was incorporated in 2002 and is based in Perth, Australia.
Australian Market Performance
- 7 Days: 0.1%
- 3 Months: 7.9%
- 1 Year: 7.8%
- Year to Date: 6.3%
The market has been flat in the last week, however the Materials sector is down 3.1%. As for the longer term, the market has risen 7.8% in the past 12 months. Looking forward, earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading